Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523663 · ClinicalTrials.gov registry record
System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2
A clinical trial, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- 46
- Enrollment target
NCT03523663 is a clinical trial that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 46 participants.
The verdict
NCT03523663 was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- 46 participants
- Enrollment target
Study Summary
The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) individually. If successful, it will change the way in which the dose of CNS stimulant for treating ADHD is determined for children in need of therapeutic intervention. The project will be focused on developing the necessary methodology to analyze the children's data with the drift-decision model (DDM), and to develop the required technology, i.e., a computer game with which to measure cognitive/behavioral function and its validation with eye-tracking measurements.
Interventions
- OTHER no intervention. measure eye movement data
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-09-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523663
The ClinicalTrials.gov registry entry for NCT03523663 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which no intervention. measure eye movement data is the first listed.
NCT03523663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523663 about?
NCT03523663 is a clinical study titled "System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2". The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (...
What is the current status of trial NCT03523663?
This trial is currently terminated. The enrollment target is 46 participants. The study started on 2016-01. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03523663?
The interventions under investigation include: no intervention. measure eye movement data (OTHER).
Who is sponsoring clinical trial NCT03523663?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.